Davion Healthcare Announces US$25 Million Acquisition of Humaskan Medical Technology IP
Davion Healthcare completed its first acquisition since last week's Nasdaq direct listing, buying the IP for WoundSkan (a smart wound-monitoring dressing) and the Spektra Lateral Flow Test for US$25 million. Consideration comprises US$2.5 million in cash plus 1,730,770 new Davion shares valued at a fixed US$13.00 per share; shares are issued after a 90-day deferral with sellers capped at 10% of five-day average daily volume for 90 days thereafter.
Key figures
- Deal Value Usd
- 25000000
- Shares issued
- 1730770
- Cash component
- $2.5 million
- Share component value
- approximately US$22.5 million
- Contractual share value
- 13
- Acquisition finance bond
- £30 million five-year senior secured bond
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.